Ovid Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 499.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Details
| Name | Ovid Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 23 |
| Founded | 2014 |
| Ipo Date | 2017-05-05 |
| Ceo | Margaret Alexander |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US6904691010 |
| Cusip | 690469101 |
| Cik | 0001636651 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Margaret Alexander | Chief Executive Officer, President and Director |
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder and Executive Chairman |
| Jeffrey A. Rona | Advisor |
| Charles Ross Carter M.B.A., M.S. | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Secretary |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Victoria Fort | Chief Strategy Officer |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Kevin Norrett M.B.A., M.S. | Chief Business Officer |
Contact
| Address | Hudson Commons, 441 9th Avenue, New York, New York 10001, United States |
| Phone | 646 661 7661 |
| Website | https://www.ovidrx.com |